iwMPN 2026 highlights: combination strategies in frontline myelofibrosis and novel agents in the ...

This podcast episode features two expert-led roundtable discussions from the recent 4th International Workshop on Myelodysplastic Syndromes and Myeloproliferative Neoplasms (iwMDS/iwMPN 2026) and focuses on updates in myelofibrosis from the meeting. First, Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Pankit Vachhani, MD, University of Alabama at Birmingham, Birmingham, AL, and Nikolai Podoltsev, MD, PhD, Yale School of Medicine, New Haven, CT, provide an update on combination strategies in frontline myelofibrosis and discuss three agents in Phase III development as partners for ruxolitinib: selinexor, navtemadlin, and pelabresib. The experts also comment on whether these agents are more likely to be used upfront or as add-on therapy in patients with a suboptimal response to frontline JAK inhibitor treatment.  In the second discussion, Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Joseph Scandura, MD, PhD, Weill Cornell Medicine, New York, NY, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Rupali Bhave, MD, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, outline novel approaches in the second-line setting that move beyond the targeting of JAK/STAT signaling. They also highlight the wider consequences of myelofibrosis, including pulmonary hypertension, and the opportunity for closer collaboration with cardio-oncology.